Generic, biosimilar and branded cancer medicines: making an informed choice

First, separate the medicine name from the brand

The generic name identifies an active ingredient, such as capecitabine or imatinib. A brand name identifies a product sold by a particular manufacturer. In India, a generic medicine may itself be sold under a brand name; “branded” and “generic” are not always opposites.

Before comparing prices, ask the pharmacist to write down the active ingredient, strength, formulation, pack size and manufacturer. Products with similar names or packaging may not be interchangeable. The same total amount in a box may provide a different number of prescribed doses.

Generic, reference medicine or biosimilar?

Reference or originator medicine

The established product against which a generic or biosimilar may be compared. It is often known by its original brand name.

Generic medicine

A version of a medicine with the same active ingredient. For a standard generic, the strength, dosage form and route must match the relevant reference product, with appropriate evidence of quality and equivalence.

Biosimilar or similar biologic

A highly similar version of a biological medicine, assessed against a reference product. Biological medicines are made using living systems and are more complex than conventional chemical medicines. Trastuzumab and rituximab are examples.

What does equivalence mean for a generic?

For many tablets, bioequivalence testing compares how quickly and how much of the active ingredient reaches the bloodstream. It does not mean that every tablet contains only a proportion of the stated dose. Quality standards also address identity, strength, purity and manufacturing.

Colour, shape and inactive ingredients can differ. Tell the pharmacist about allergies or difficulties swallowing, and check the label when a pack looks different. Do not assume that a different-looking tablet means the prescription has changed.

Some formulations need particular care. Standard and modified-release tablets, liposomal and conventional injections, or intravenous and under-the-skin products should not be substituted on the basis of the ingredient name alone. The treating team should confirm the exact formulation.

What is checked for a biosimilar?

A biosimilar is expected to have no clinically meaningful differences in safety or effectiveness from its reference medicine for its approved uses. Assessment brings together detailed laboratory comparisons and the additional evidence required by the regulator.

Biological medicines naturally have some variation, including between batches of the original product. The question is whether the differences fall within acceptable limits and matter clinically.

A biosimilar may be authorised for an indication without repeating a large trial in that exact cancer when the regulator accepts the scientific justification. This is called extrapolation. It is different from assuming that every product can be used for every purpose.

Approval relates to the particular product and regulator. Information from the US Food and Drug Administration or European organisations explains the principles; it does not prove that every product sold in India has those approvals. Ask your oncologist or hospital pharmacist to confirm the Indian approval and evidence for the product being offered.

Changing products during a treatment course

A planned switch may be reasonable when your team considers the products suitable. You should know what is changing, why it is changing and whether any instructions will be different. An unplanned substitution at the pharmacy should be checked with the prescriber.

Confirm the dose in milligrams and the number of tablets or vials. Also check concentration, route, food instructions and any preparation requirements. Do not carry across a tablet count from an old pack without checking its strength.

For biological medicines, ask the treatment unit to record the brand and batch number. This helps identify exactly what was given if a reaction needs investigation. Keep your treatment record and packaging details where practical.

Report an unexpected symptom after a switch, but do not assume the new brand caused it. The team can assess the timing, other medicines and alternative causes. Severe breathing difficulty, swelling, faintness or another serious reaction needs urgent care.

Compare the total treatment cost

Ask for a written estimate for the prescribed course, not just the price of one vial. The number of doses, vial sizes, wastage, infusion charges, tests and supportive medicines can change the total. A very large advertised discount may use a different starting price or pack size.

Ask the hospital pharmacy about suitable lower-cost products, stock continuity and any patient-assistance scheme for which you may qualify. If a programme offers some doses without charge, check eligibility, what must first be purchased and whether support continues for the planned course.

Insurance and government schemes may have rules about the product, hospital or treatment package. Obtain confirmation before buying. Current prices and programme terms change; this article does not promise a particular saving or that a specific medicine is always available.

If cost is making you consider skipping doses or stopping treatment, tell the team promptly. There may be a different product, support option or treatment approach worth discussing. You should be involved in weighing benefits, risks and affordability.

Protect the supply and storage of your medicine

Use a licensed pharmacy or the supply route agreed with your hospital. Keep the invoice and original packaging. Check the medicine name, strength, manufacturer, seal, batch number and expiry date. Packaging checks are useful, but cannot by themselves guarantee authenticity.

Be cautious about an unusually cheap offer with no invoice, an unidentified seller or a product that arrives without a clear storage history. Ask the pharmacy to resolve uncertainty before the medicine is used.

Follow the storage instructions for the exact product. Some biological medicines need refrigeration, but the permitted temperature and time outside a refrigerator vary. Ask the pharmacy to organise suitable transport; placing a medicine directly against ice or freezing it can damage it.

Before purchasing an infusion medicine elsewhere, check whether the treating hospital will accept it and what documentation it requires. Do not assume that bringing your own medicine will be possible or cheaper overall.

Six useful questions before choosing

• What are the active ingredient, formulation, strength and manufacturer?
• Is this the reference product, a generic or a biosimilar?
• Is this exact product approved for use here, and why do you recommend it for me?
• If we switch, do the dose, route, tablet count or instructions change?
• What is the realistic cost of the planned course, including administration and monitoring?
• Where should it be obtained, and who will arrange storage and report a suspected problem?

Common questions

Related reading

• Care, costs and support
• Cancer medicines A–Z
• Taking cancer tablets safely at home